Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
12/2009
12/17/2009US20090312546 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
12/17/2009US20090312543 Pyrazole compounds useful as protein kinase inhibitors
12/17/2009US20090312520 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer
12/17/2009US20090312390 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
12/17/2009US20090312368 Pyridine Analogues IV
12/17/2009US20090312355 Non-Flushing Niacin Analogues, and Methods of Use Thereof
12/17/2009US20090312349 Anti-inflammatory medicaments
12/17/2009US20090312343 Quinazoline derivatives as tyrosine kinase inhibitors
12/17/2009US20090312341 Cyclic amine bace-1 inhibitors having a heterocyclic substituent
12/17/2009US20090312327 Pyrrolidine derivatives as nk2 receptor antagonists
12/17/2009US20090312326 Substituted imidazoles
12/17/2009US20090312325 Quinoline Derivatives As Phosphodiesterase Inhibitors
12/17/2009US20090312323 Compounds for the treatment of spinal muscular atrophy and other uses
12/17/2009US20090312314 Heteroaromatic monoamides as orexinin receptor antagonists
12/17/2009US20090312313 Compound having tgfbeta inhibitory activity and pharmaceutical composition comprising the same
12/17/2009US20090312308 Compounds and compositions as hedgehog signaling pathway modulators
12/17/2009US20090312307 Heterocyclo inhibitors of potassium channel function
12/17/2009US20090312305 Bicyclic compounds having activity at the cxcr4 receptor
12/17/2009US20090312304 Organic compounds
12/17/2009US20090312276 Compositions and Methods for Treating Cancer
12/17/2009US20090311266 Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
12/17/2009CA2727684A1 Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
12/17/2009CA2727680A1 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
12/17/2009CA2727607A1 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
12/17/2009CA2727245A1 Imidazole derivatives useful as inhibitors of faah
12/17/2009CA2727242A1 Pyrazole derivatives useful as inhibitors of faah
12/17/2009CA2727073A1 Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
12/17/2009CA2726666A1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
12/17/2009CA2726158A1 Compounds and compositions useful for the treatment of malaria
12/17/2009CA2726102A1 Tetrazole compounds as orexin receptor antagonists
12/17/2009CA2725755A1 Substituted pyrroles and methods of use
12/17/2009CA2725654A1 Imidazolidine derivatives
12/17/2009CA2720285A1 Pyrrolidine ether derivatives as nk3 receptor antagonists
12/16/2009EP2133348A1 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
12/16/2009EP2133347A1 1-biarylazetidinone derivatives
12/16/2009EP2133340A1 Novel benzazepine derivatives
12/16/2009EP2133334A1 Heterocyclic derivatives as HDAC inhibitors
12/16/2009EP2133331A1 5-membered heterocyclic derivative and use thereof for medical purposes
12/16/2009EP2132987A1 Nematicidal agent composition and method of using the same
12/16/2009EP2132198A1 Solid forms of a raf kinase inhibitor
12/16/2009EP2132197A2 Substituted pyrimidines as adenosine receptor antagonists
12/16/2009EP2132196A1 Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
12/16/2009EP2132195A1 Acetone solvate of phthaloyl amlodipine
12/16/2009EP2132193A1 Substituted pyrrolidine amides, the production thereof, and the use thereof as medications
12/16/2009EP2132177A1 Pim kinase inhibitors and methods of their use
12/16/2009EP2132176A1 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
12/16/2009EP2131846A1 Novel dosage form
12/16/2009EP1888567B1 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors
12/16/2009EP1805165B1 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mglur3 receptor antagonists
12/16/2009EP1778684B1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR
12/16/2009EP1576159B9 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
12/16/2009EP1322634B1 N-phenyl-2-pyrimidine-amine derivatives
12/16/2009CN101605782A 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular IKK inhibitors
12/16/2009CN101605781A Aryl carboxylic acid cyclohexyl amide derivatives
12/16/2009CN101605780A New 2, 4-dianilinopyrimidines, preparation thereof as drugs,pharmaceutical compositions and use thereof essentially as IKK inhibitors
12/16/2009CN101605779A Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
12/16/2009CN101605778A Certain substituted amides, method of making, and method of use thereof
12/16/2009CN101605777A Imidazoles as aldosterone synthase inhibitors
12/16/2009CN101605776A 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
12/16/2009CN101605767A Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
12/16/2009CN101605766A Pyrimidines derivatives and their use as kinase inhibitors
12/16/2009CN101605761A Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene
12/16/2009CN101605758A Methods for treating hepatitis C
12/16/2009CN101602757A 4-substituent-2-amido pyrimidine compound and preparation method thereof
12/16/2009CN101602741A Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
12/16/2009CN101602732A Derivative of acyl thiourea pyridine, method for preparing same and application thereof
12/16/2009CN101602731A Metalloproteinase inhibitors
12/16/2009CN101602708A Aryl alkanol piperidine derivative and application thereof as antidepressive medicine
12/16/2009CN100569782C Zinc complex luminescent material
12/16/2009CN100569769C Compounds with antibacterial activity
12/16/2009CN100569767C Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
12/15/2009US7632955 Treatment of peroxisome proliferation activated receptor diseases such as diabetes, skin disorders or high blood pressure
12/15/2009US7632951 Inhibitors of integrin ανβ6
12/15/2009US7632950 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
12/15/2009US7632949 condensation of isophthalic acic dichloride (IPC) with sterically hindered amines of the type tetraalkylpiperidine; by using organic solvents or mixtures of organic solvents with water and by an optimized combination of temperature and pressure the yield is much higher than by using water alone
12/15/2009US7632865 N-(4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenyl)-2-chloro-5-nitrothiobenzamide, for example; useful as preventive or therapeutic medicines for diseases accompanied by hyperactivated immune functions
12/15/2009US7632858 For example, 1-(4-Cyano-2-ethyl-3-(trifluoromethyl)phenyl-1-carbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester; may be used in treatment of diseases or disorders associated with androgen receptor activity, such as maintenance of muscle strength and function in the elderly
12/15/2009US7632857 Histamine H3 receptor agents, preparation and therapeutic uses
12/15/2009US7632849 Indazolamides with analgesic activity
12/15/2009US7632845 Phenyl quinolines and their use as estrogenic agents
12/15/2009US7632840 Quinazoline compounds for the treatment of hyperproliferative disorders
12/15/2009US7632832 Antagonist for calcitonin gene related peptide (Cgrp); azepinone ligands; migranes; headaches; 1-[(2-methoxyethyl)-2-oxo-6-phenylazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
12/15/2009US7632829 Diazepan derivatives
12/15/2009US7632578 Containing imidazo-pyridine compound
12/15/2009CA2607940C Bir domain binding compounds
12/15/2009CA2529611C Pyrimidine derivatives for the treatment of abnormal cell growth
12/15/2009CA2502264C N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials
12/10/2009WO2009149259A2 Processes for preparing tetrahydroisoquinolines
12/10/2009WO2009149258A2 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
12/10/2009WO2009148004A1 Novel compound and pharmaceutical application of same
12/10/2009WO2009147843A1 Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof
12/10/2009WO2009147626A2 Anhydrous amorphous form of imatinib mesylate
12/10/2009WO2009147211A1 New compounds v
12/10/2009WO2009147190A1 Novel compounds
12/10/2009WO2009147121A1 Carboxyl substituted indoles for use as ppar alpha modulators
12/10/2009WO2009147079A1 3,4-dihydropyrimidine trpa1 antagonists
12/10/2009WO2009146696A1 Use of indole-3-carboxylic esters for inhibiting microsomal prostaglandin e2 synthase
12/10/2009WO2009146648A1 Amide compounds, preparation methods and uses thereof
12/10/2009WO2009109616A3 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
12/10/2009WO2009108384A3 Compounds and compositions that cause non-apoptotic cell death and uses thereof
1 ... 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 ... 1080